Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Net Margin (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Net Margin for 4 consecutive years, with 36.72% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 21443.0% to 36.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 126.24% through Dec 2025, up 47884.0% year-over-year, with the annual reading at 126.24% for FY2025, 47884.0% up from the prior year.
  • Net Margin for Q4 2025 was 36.72% at Phathom Pharmaceuticals, up from 60.53% in the prior quarter.
  • The five-year high for Net Margin was 1473.65% in Q1 2022, with the low at 11665.1% in Q4 2023.
  • Average Net Margin over 4 years is 1164.87%, with a median of 191.52% recorded in 2025.
  • The sharpest move saw Net Margin plummeted -1223745bps in 2023, then surged 1141396bps in 2024.
  • Over 4 years, Net Margin stood at 572.35% in 2022, then crashed by -2138bps to 11665.1% in 2023, then surged by 98bps to 251.15% in 2024, then skyrocketed by 85bps to 36.72% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 36.72%, 60.53%, and 191.52% for Q4 2025, Q3 2025, and Q2 2025 respectively.